• Advances in prevention, treatment, and management are turning cancer into a chronic disease.
• The numbers of people diagnosed and living with cancer continue to rise while the number of oncology physicians ready to treat this population is projected to fall.
• Healthcare reform in the US has shed more light on this growing shortfall of trained oncology clinicians.
The Journal of the Advanced Practitioner in Oncology (JAdPrO)
The mission of the Journal of the Advanced Practitioner in Oncology (JAdPrO) is to improve the quality of care for patients with cancer, support critical issues in advanced practice in oncology and recognize the expanding contributions of advanced practitioners in oncology. The essential objectives of JAdPrO are:
How do NPs and PAs differ from the Oncology Nurse?
• Like an RN, a nurse practitioner performs many tasks involved in examining and treating patients.
• In most states, NPs are licensed to prescribe medications and may perform many of the same tasks as physicians, including diagnosing patient conditions.
• NPs do not require the supervision of a physician. Furthermore, NPs may act as primary-care providers, while RNs cannot.
• A PA performs many of the same tasks as an RN or NP. However, a PA must work under the supervision of a physician or surgeon and cannot operate an independent practice. PAs can, in many parts of the US, prescribe medications. They can also serve as primary care providers, always under the supervision of a licensed physician.
The Need
Mission Statement
The Audience
• To publish topics across the cancer trajectory for the nurse practitioner, clinical nurse specialist and physician assistant
• To support professional development of the advanced practitioner in oncology
• To promote interprofessional collaboration
• To uphold the highest ethical and professional standards
• To provide information that will enhance the quality of care for the patient with cancer
The journal will publish four issues in 2010 and six issues in 2011. JAdPrO also will be available online at www.advancedpractitioner.com.
Sections include:
While oncologists will continue to provide handson patient care, integrating NPs and PAs has significant potential to extend the supply of oncologist services… 
Bendamustine
Amy GOOdRICh, mSN, CRNP-AC T he treatment of lowgrade lymphoid malignancies has seen major progress in the past decade, with improved response rates and survival in indolent B-cell lymphomas (Hiddemann et al., 2005; Herold et al., 2007) and historical comparisons suggestive of improved survival in chronic lymphocytic leukemia (CLL; Byrd et al., 2005; Keating et al., 2005) . Approximately 26,500 new cases of low-grade nonHodgkin's lymphoma (NHL) and 15,490 new cases of CLL were diagnosed in the United States in 2009 (Jemal et al., 2009) .
Despite this recent progress, patients with NHL or CLL are still expected to relapse and require multiple treatment regimens over many years. This reality makes it critical to have extensive, effective therapy options available (Cheson & Rummel, 2009) . One agent approved for use in patients with NHL or CLL is bendamustine (Treanda).
Class of Agent
Bendamustine is a novel hybrid agent created in the early 1960s in the former German Democratic Republic (GDR), also known as East Germany. Relocation of the nitrogen-mustard group to position 5 on a benzimidazole ring resulted in an agent with a structure to that of alkylating agents and purine analogs (Ozegowski et al., 1971; Leoni et al., 2008) . The effect of the benzimidazole ring on the clinical activity of bendamustine is unknown. Despite the use of bendamustine in the GDR for over 30 years, the drug underwent few studies considered validated by today's standards (Hartmann & Zimmer, 1972; Cheson & Rummel, 2009) . After German reunification, trials were initiated to assess bendamustine's value in a variety of hematologic and solid malignancies. (Cheson & Rummel, 2009 ).
Mechanism of Action
Bendamustine's antitumor effects include DNA damage through double-and single-strand DNA crosslinks and down-regulation of mitotic checkpoint genes that regulate DNA synthesis and cell division (Leoni et al., 2008) . The concomitant activity of these pathways may further increase the cytotoxicity of bendamustine through a process called mitotic catastrophe, a form of necrotic cell death that occurs independently of normal apoptosis (Niemeyer et al., 2005) . Bendamustine also has been shown to be active in tumors refractory to other chemotherapies, including alkylating agents (Friedberg et al., 2008; Strumberg et al., 1996; Leoni et al., 2008; Leoni et al., 2003) . . Chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute myelogenous leukemia (AML), and myelodysplatic syndromes (MDS) represent the most common hematologic diseases in adults, with the majority of these diagnoses in patients over the age of 65 (Table 1) . 
Abstract
Chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), multiple myeloma (MM), acute myelogenous leukemia (AML) and myelodysplatic syndromes (MDS) represent the most common hematologic diseases in adults, with the majority of diagnoses in patients over the age of 65. Older adults (> 65 years) are expected to exceed 20% of the overall United States population by the year 2030. Given the predicted increase in size of the older adult population along with the incidence of these cancers, health care providers must familiarize themselves with the needs of older adults with hematologic malignancies. Risk-adapted treatment approaches include primarily disease-specific prognostication. The effect of comorbidities and functional status on treatment outcomes have been evaluated in recent clinical trials. Functional decline is associated with loss of independence and decreased quality of life. Most of these hematologic diseases are not curable; therefore, the preservation of quality of life and independent function should remain a priority. Careful consideration of the patient and disease-related factors together with the expectations of the patient and the consistent availability of caregivers is necessary to provide the best outcome. Familiarity with recent clinical trials data, risk-adapted treatment guidelines, and the complex attributes of the older adult will provide the advanced practitioner sound clinical management strategies and effectively eliminate chronologic age alone as a barrier to treatment of common hematologic malignancies. H ereditary colorectal cancer syndromes can be divided into polyposis and nonpolyposis groups. Despite the implications of the term "nonpolyposis," this syndrome is associated with polyps, though they are usually fewer in number. Advanced practitioners may use the presence of 10 or more polyps as a rough estimate when considering genetic testing for a polyposis syndrome (Hampel, 2009) . Histological characteristics will also help differentiate between hamartomatous or adenomatous polyposis syndromes.
Hamartomas are defined as overgrowths of cells and tissues native to the anatomic location in which they occur (Odze & Hornick, 2009 ). In the gastrointestinal tract, hamartomas typically incorporate both stroma and Case Study D.R. is a healthy 42-year-old male who presented to the High Risk Familial Cancer Clinic because his father had been recently diagnosed with attentuated familial adenomatous polyposis. His father, L. R., age 65 years with a history of hypertension and heart failure, had visited his primary care practitioner (PCP) complaining of fatigue. His PCP obtained a complete blood cell count and examined his stool for occult blood. L.R. was found to have microcytic anemia (hemoglobin of 8.6/dL, hematocrit of 25.8%, mean corpuscular volume of 76 fL) and guaiac-positive stools; his PCP referred him for a colonoscopy. Although L.R. was 65 years old, this was his first colonoscopy. Over 100 polyps with variable pathology were identified throughout the colon and rectum, including hyperplastic polyps and tubular and tubulovillous adenomas. The largest tubulovillous adenoma was 1 cm in size. L.R. was referred for genetic counseling and, after informed consent was obtained, underwent testing for familial adenomatous polyposis. The test results showed a deleterious mutation in the adenomatous polyposis coli gene (exon 4:c.426_427delAT). L.R. underwent a total proctocolectomy with ileal pouch anal anastomosis. After receiving genetic counseling, D.R. received site-specific testing for the genetic mutation identified in his father and subsequently tested positive for the same mutation. Of note, he has three children, ages 10, 12, and 14. All three children tested positive for the same mutation (see pedigree in Figure 1) . J Adv Pract Oncol 2010;1:XX-XX
Management of Chemotherapy-Induced Diarrhea
Carolyn Grande, CRNP, AOCNP Hospital of the University of Pennsylvania Philadelphia, Pennsylvania
Chemotherapy-induced diarrhea (CID) is a complication of several chemotherapeutic agents, most notably the fluoropyrimidines (Buroker, O'Connell, Wieand, et al., 1994) and topoisomerase I inhibitors (Saltz, Cox, Blanke, et al., 2000) . Early intervention is the key to optimal management and prevention of dehydration, electrolyte imbalances, and associated sequelae. Without proper management, CID can have a negative impact on patient quality of life and treatment outcomes.
Pathophysiology
The etiology of CID is not clearly understood. It is thought that chemotherapy toxicity initiates the destruction or alteration of rapidly dividing crypt cells in the intestinal epithelium, thereby inhibiting its absorptive capacity and leading to diarrhea. The disruption between the balance of absorptive and secretory abilities can result in increased loss of fluid and electrolytes through the stool (Saltz, 2003) .
Definition and Assessment
Although there are different definitions of diarrhea, the mainstay is from the Common Terminology Criteria for Adverse Events (CTCAE), which states that diarrhea is a disorder characterized by frequent and watery bowel movements (National Cancer Institute, 2009) . The CTCAE bases this definition on the amount of stools above what is normal for the patient. A grading system of 1 through 5 is utilized to identify severity of diarrhea, with 1 being mild and 5 equivalent to death, as shown in Table 1 . Note. ADLs = activities of daily living. Based on information from the National Cancer Institute, 2009. A semi-colon indicates "or" in the grade description.
A thorough evaluation of diarrhea begins with a comprehensive history, exploration of patient-reported symptoms, dehydration assessment, and physical exam. Assessment strategies are outlined in Table 2 .
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